Last reviewed · How we verify

NCT06711653

Development of Bone-vestibular Evoked Myogenic Potential

Completed NA Last updated 2 December 2024
What this trial tests

NA trial testing Vestibular evoke myogenic potential in Noise in 20 participants. Completed in 1 May 2023.

Timeline
7 November 2022
Primary endpoint
1 May 2023
1 May 2023

Quick facts

Lead sponsorTaipei City Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment20
Start date7 November 2022
Primary completion1 May 2023
Estimated completion1 May 2023
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Taipei City Hospital

Who can join

Adults 20 to 40, any sex, with Noise or Vestibular Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the effects of different masking conditions on cervical vestibular evoked myogenic potential (cVEMP) responses. Vertical-axis vibrations (VAVs) of 500-Hz short-tone bursts (STB500) and 750-Hz short-tone bursts (STB750) were used to elicit cVEMP responses. These stimuli were delivered through a Mini-Shaker placed at the vertex (Cz) under three masking conditions: no masking (NOM), speech noise masking (SNM), and random interstimulus-interval tone bursts (rISITB). The study focused on testing protocols that can potentially improve unilateral VEMP testing and explore its clinical applicability.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Taipei City Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06711653.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing